A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Inclusion Criteria

• •Male or Female, between 18 and 56 years old;
• •diagnosed with SLE according to 2019 EULAR/ACR SLE classifications;
• •anti-Nuclear Antigen Ab positive (titer NLT 1:80) and/or dsDNA ab positive and/or Anti-Sm ab positive at screening;
• •at screening, SLEDAI-2000 scoring NLT 8 points, if low complement scoring and/or anti-dsDNA ab scoring is available, the SLEDAI-2000 scoring except low complement and anti-dsDNA ab should be NLT 6 points;
• •should be subjected to at least 6 months of standard treatment for SLE, and disease active at least two months before screening;
• •good organ functions;
• •trial participants whose partner is fertile agree to use effective contraceptives til 24 months post transfusion, fertile female participants should have negative urine/blood pregnancy test results (participants who were sterilized or menopause for MT 12 months is not considered fertile);
• •voluntary participates this trial and can comprehend and sign ICF.